Literature DB >> 24606672

Potent bactericidal efficacy of copper oxide impregnated non-porous solid surfaces.

Alastair B Monk1, Vikram Kanmukhla, Ken Trinder, Gadi Borkow.   

Abstract

BACKGROUND: The role of fomites and the environment in nosocomial infections is becoming widely recognized. In this paper we discuss the use of Cupron copper oxide impregnated non-porous solid surface in the hospital setting and present in vitro testing data via USA Environmental Protection Agency (EPA) approved testing protocols that demonstrate the efficacy of these products to assist in reduction in environmental contamination and potentially nosocomial infections.
RESULTS: The two countertops tested passed all the acceptance criteria by the EPA (>99.9% kill within 2 hours of exposure) killing a range of bacterial pathogens on the surface of the countertops even after repeated exposure of the countertops to the pathogen, and multiple wet and dry abrasion cycles.
CONCLUSIONS: Cupron enhanced EOS countertops thus may be an important adjunct to be used in hospital settings to reduce environmental bioburden and potentially nosocomial infections.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24606672      PMCID: PMC3973859          DOI: 10.1186/1471-2180-14-57

Source DB:  PubMed          Journal:  BMC Microbiol        ISSN: 1471-2180            Impact factor:   3.605


Background

Hospital Acquired Infections (HAI) have exacted a heavy toll worldwide with over 2 million patients annually contracting an infection in the US [1], being one of the leading causes of death in the US behind cancer and strokes [2]. In Europe, out of 3 million HAI [3] approximately 50,000 resulted in death [4], and in Australia more than 177,000 HAI occur per year [5] whilst in the province of Quebec, Canada the rate of HAI are estimated to be around 11% [6]. The HAI rates in developing countries are significantly higher [7-9]. According to the USA Center for Disease Control (CDC) some of the predominant HAI organisms are Staphylococcus aureus, Pseudomonas aeruginosa, and Enterobacter species [10]. Methicillin resistant S. aureus accounts for 50% of HAI associated with multidrug resistant pathogens [10]. The Extended Prevalence of Infection in Intensive Care (EPIC II) study demonstrated a 50% HAI rate in ICU patients sampled from over 75 countries and two of the most predominant organisms were resistant Staphylococci and P. aeruginosa[11]. HAI are associated with considerable mortality, morbidity and costs [2,12]. Recent intervention efforts including improvement of national surveillance, use of aggressive antibiotic control programs, healthcare staff education for improved hygiene, isolation of infected patients, use of disposable equipment, cleaning and disinfection of environmental surfaces and equipment, improvement of cleaning equipment and sanitary facilities, increase in nursing and janitorial resources and better nutrition [13-17], have been shown to reduce HAI rates. However further supplemental interventions are required. The link between contaminated hard surfaces to HAI has been demonstrated [18-28] and an antimicrobial protected touch surface would assist in reduction of pathogen buildup upon touch surfaces as long as that activity can be indisputably demonstrated. Thus, our objective was to demonstrate the efficacy of two solid surface countertops incorporating copper (I) oxide in killing a range of pathogens according to protocols that were approved by the USA Environmental Protection Agency (EPA).

Methods

Bacterial strains

The following bacterial strains were tested: Staphylococcus aureus (ATCC 6538); Enterobacter aerogenes (ATCC 13048); Pseudomonas aeruginosa (ATCC 15442); Methicillin resistant Staphylococcus aureus (MRSA)(ATCC 33592); and Escherichia coli 0157:H7 (ATCC 35150).

Materials

The studied countertops were composed of homogenous blends of polyester, acrylic alloys and fillers, inert pigment and dyes, with (test samples) or without (control samples) Cupron’s 16% copper (I) oxide weight/weight. Three and two separate manufacturing lots of the test and control countertop samples were tested, respectively. A total of 1500 pieces, cut into one inch by one inch squares (Figure 1), 300 per each manufacturing lot, were tested. The countertops were examined by Scanning Electron Microscopy (SEM) and Energy-dispersive X-ray spectroscopy (EDS) by using Hitachi FE-SEM SU-70. The Cupron Enhanced EOS Surface is a novel polymeric solid surface that has all the properties of a solid surface including hardness, firmness, and the ability to be easily cleaned and shaped or fashioned with the antimicrobial ability of copper. The surface can be easily refinished and repaired in the event of damage or aesthetic appeal. The surfaces are currently available in two color choices due to the addition of pigments to alter the color of the surfaces at the time of manufacture. The surface is produced by mixing a blend of acrylic and polyester resins with copper oxide and pigments, which is then heated until liquified and poured into casting molds. The material is allowed to cure allowing the polymerization of the material to produce a solid surface which can then be cut and shaped to produce a final product or installed surface.
Figure 1

SEM pictures and EDS analysis of a representative countertop containing copper oxide particles. A. A representative picture of a tested countertop impregnated with copper oxide; B. A SEM imaging of the Countertop (white dots indicating copper oxide particles; C. EDS imaging of the Countertop (purple dots indicating the copper oxide); D. cut through SEM imaging of the Countertop (white dots indicating copper oxide particles); and E. corresponding EDS spectra of D, showing a peak corresponding to copper.

SEM pictures and EDS analysis of a representative countertop containing copper oxide particles. A. A representative picture of a tested countertop impregnated with copper oxide; B. A SEM imaging of the Countertop (white dots indicating copper oxide particles; C. EDS imaging of the Countertop (purple dots indicating the copper oxide); D. cut through SEM imaging of the Countertop (white dots indicating copper oxide particles); and E. corresponding EDS spectra of D, showing a peak corresponding to copper.

Biocidal testing protocols

The biocidal testing of the countertops was conducted by an independent laboratory, MicroBiotest, a division of Microbac Laboratories, Inc. Sterling, VA, using Good Laboratory Practice (GLP) according to protocols pre-approved by the USA EPA.

Protocol 1- sanitizer activity

The carriers were cleaned with 70% isopropyl alcohol, rinsed with deionized water, and allowed to air dry. After steam sterilization for 15 minutes at 121°C, each carrier was placed into a plastic Petri dish matted with two pieces of filter paper using sterile forceps. Two or three lots of manufacturing of each test material were tested per microorganism. Five replicates of each material were used in each test. Organisms from stock cultures were transferred to Tryptic Soy Broth and incubated for 24 hours at 35-37°C (25-30°C for ATCC 13048). Two loopfuls of culture were transferred consecutively daily for three days for the inoculation stocks and the pellicle of bacteria were aspirated. Daily transfers were done for at least 3 consecutive days but for no more than 10 days. To this culture 0.25 ml of heat-inactivated fetal bovine serum (FBS) and 0.05 ml of Triton X-100 were added to 4.7 ml bacteria suspension to yield 5% FBS and 0.01% Triton X-100 organic soil load. The challenge microorganism titer was determined by serially diluting a final 48 hour culture using phosphate buffered solution (PBS) and selected dilutions were plated in duplicate using Tryptic Soy Agar (TSA) pour plates. Carriers were inoculated with 0.02 ml of the 48 hour culture. The bacterial inoculum per experiment is detailed in Table 1. All control plates were incubated in parallel to the test plates. The inoculum was spread to within ~1/8 inch of the control or test carrier before air drying for 20–40 minutes at 35-37°C and 38-42% relative humidity. After 120 minutes exposure at 21°C, the carriers were transferred to 20 ml neutralizer solution (2x Letheen broth [29]) and sonicated for 5 minutes and rotated to mix. Within one hour serial dilutions (10−1 to 10−4) were made in PBS and plated using TSA and incubated for 48 hours at 35-37°C for colony observation and enumeration, taking into account also the 20 fold dilution used to retrieve the bacteria from the carriers. The following controls were performed: culture purity control - each prepared culture was streaked using TSA for purity control; organic soil purity control - duplicate 1 ml aliquots of organic soil were plated in TSA pour plates for sterility control; neutralizer sterility control – a jar containing the neutralizer was incubated with the test plates and observed for growth or no growth; carrier sterility control – an uninoculated test (per lot) and control carrier was put in independent jars containing the neutralizer, incubated and observed for growth or no growth; carrier viability control – for each challenge microorganism, a single inoculated control carrier was subcultured in a jar containing the neutralizer, incubated and the neutralizer observed for growth or no growth; and neutralization confirmation control – for each challenge microorganisms, per lot of the test article, a single sterile test carrier was put in individuals jars containing 20 ml of the neutralizer. To each jar a 1 ml aliquot of the diluted inoculum was added to reach ~100 colony forming units (CFU)/ml in the neutralizer. The jar was mixed and the 1 ml inoculum was removed and plated in duplicate.
Table 1

CFU recovered from control samples

Microorganism
Protocol
Replicate
Inoculum
Titers recovered
Average
   CFU/carrierCFU/carrierCFU/carrier
S. aureus
1
1
0.22 × 108
8.4 × 105
7.5 × 105
 
 
2
 
7.0 × 105
 
 
 
3
 
7.2 × 105
 
 
2 - initial
1
0.42 × 108
1.1 × 106
1.3 × 106
 
 
2
 
1.6 × 106
 
 
 
3
 
1.2 × 106
 
 
 
4
 
1.3 × 106
 
 
2 - Final
1
0.46 × 108
9.9 × 105
1.1 × 106
 
 
2
 
1.1 × 106
 
 
 
3
 
1.3 × 106
 
 
 
4
 
1.0 × 106
 
 
3 - 2 hours
1
0.38 × 108
8.2 × 105
9.3 × 105
 
 
2
 
1.0 × 106
 
 
 
3
 
9.4 × 105
 
 
3 - 6 hours
1
 
2.0 × 106
1.8 × 106
 
 
2
 
1.8 × 106
 
 
 
3
 
1.7 × 106
 
 
3 - 12 hours
1
 
2.5 × 106
2.5 × 106
 
 
2
 
2.4 × 106
 
 
 
3
 
3.7 × 106
 
 
3 - 18 hours
1
 
3.7 × 106
3.6 × 106
 
 
2
 
3.6 × 106
 
 
 
3
 
3.5 × 106
 
 
3 - 24 hours
1
 
4.6 × 106
4.6 × 106
 
 
2
 
4.6 × 106
 
 
 
3
 
4.5 × 106
 
E. aerogenes
1
1
0.38 × 109
7.4 × 106
7.9 x106
 
 
2
 
8.8 × 106
 
 
 
3
 
7.6 × 106
 
 
2 - initial
1
0.22 × 109
1.1 × 106
1.1 × 106
 
 
2
 
1.0 × 106
 
 
 
3
 
1.2 × 106
 
 
 
4
 
1.1 × 106
 
 
2 - Final
1
0.4 × 109
1.5 × 106
1.2 × 106
 
 
2
 
1.4 × 106
 
 
 
3
 
8.3 × 105
 
 
 
4
 
1.1 × 106
 
 
3 - 2 hours
1
0.38 × 109
2.0 × 106
2.0 × 106
 
 
2
 
2.1 × 106
 
 
 
3
 
2.0 × 106
 
 
3 - 6 hours
1
 
3.8 × 106
3.9 × 106
 
 
2
 
3.9 × 106
 
 
 
3
 
3.9 × 106
 
 
3 - 12 hours
1
 
5.1 × 106
4.7 × 106
 
 
2
 
5.4 × 106
 
 
 
3
 
3.6 × 106
 
 
3 - 18 hours
1
 
4.8 × 106
5.6 × 106
 
 
2
 
6.8 × 106
 
 
 
3
 
5.2 × 106
 
 
3 - 24 hours
1
 
8.5 × 106
7.9 × 106
 
 
2
 
8.4 × 106
 
 
 
3
 
6.8 × 106
 
MRSA
1
1
0.38 × 109
7.4 × 105
8.5 × 105
 
 
2
 
9.8 × 105
 
 
 
3
 
8.2 × 105
 
 
2 - initial
1
0.36 × 108
7.3 × 105
7.5 × 105
 
 
2
 
9.5 × 105
 
 
 
3
 
6.6 × 105
 
 
 
4
 
6.5 × 105
 
 
2 - Final
1
0.32 × 108
5.6 × 105
6.9 × 105
 
 
2
 
5.7 × 105
 
 
 
3
 
8.0 × 105
 
 
 
4
 
8.2 × 105
 
 
3 - 2 hours
1
0.26 × 108
4.0 × 105
4.0 × 105
 
 
2
 
3.8 × 105
 
 
 
3
 
4.2 × 105
 
 
3 - 6 hours
1
 
8.6 × 105
8.8 × 105
 
 
2
 
9.8 × 105
 
 
 
3
 
7.9 × 105
 
 
3 - 12 hours
1
 
9.9 × 105
1.0 × 106
 
 
2
 
1.2 × 106
 
 
 
3
 
9.1 × 105
 
 
3 - 18 hours
1
 
1.8 × 106
1.7 × 106
 
 
2
 
1.6 × 106
 
 
 
3
 
1.7 × 106
 
 
3 - 24 hours
1
 
1.8 × 106
1.8 × 106
 
 
2
 
1.8 × 106
 
 
 
3
 
1.7 × 106
 
P. aeruginosa
1
1
0.2 × 108
6.8 × 106
7.0 × 106
 
 
2
 
7.4 × 106
 
 
 
3
 
6.9 × 106
 
 
2 - initial
1
0.2 × 109
1.0 × 106
1.3 × 106
 
 
2
 
1.4 × 106
 
 
 
3
 
1.4 × 106
 
 
 
4
 
1.5 × 106
 
 
2 - Final
1
0.34 × 109
2.4 × 106
2.0 × 106
 
 
2
 
1.9 × 106
 
 
 
3
 
1.6 × 106
 
 
 
4
 
2.0 × 106
 
 
3 - 2 hours
1
0.3 × 109
2.6 × 105
2.5 × 105
 
 
2
 
2.5 × 105
 
 
 
3
 
2.5 × 105
 
 
3 - 6 hours
1
 
5.2 × 105
5.2 × 105
 
 
2
 
5.3 × 105
 
 
 
3
 
5.3 × 105
 
 
3 - 12 hours
1
 
7.2 × 105
7.2 × 105
 
 
2
 
7.1 × 105
 
 
 
3
 
7.4 × 105
 
 
3 - 18 hours
1
 
9.8 × 105
9.6 × 105
 
 
2
 
9.5 × 105
 
 
 
3
 
9.6 × 105
 
 
3 - 24 hours
1
 
9.8 × 105
9.7 × 105
 
 
2
 
9.2 × 105
 
 
 
3
 
1.0 × 106
 
E. coli O157:H7
1
1
0.36 × 109
6.4 × 106
6.6 × 106
 
 
2
 
6.7 × 106
 
 
 
3
 
6.6 × 106
 
 
2 - initial
1
0.24 × 109
1.5 × 106
1.1 × 106
 
 
2
 
8.3 × 106
 
 
 
3
 
1.1 × 106
 
 
 
4
 
1.1 × 106
 
 
2 - Final
1
0.22 × 109
7.8 × 105
9.4 × 105
 
 
2
 
8.0 × 105
 
 
 
3
 
1.2 × 106
 
 
 
4
 
9.9 × 105
 
 
3 - 2 hours
1
0.36 × 109
2.5 × 105
2.6 × 105
 
 
2
 
2.6 × 105
 
 
 
3
 
2.7 × 105
 
 
3 - 6 hours
1
 
5.2 × 105
5.3 × 105
 
 
2
 
5.2 × 105
 
 
 
3
 
5.4 × 105
 
 
3 - 12 hours
1
 
7.9 × 105
7.7 × 105
 
 
2
 
7.7 × 105
 
 
 
3
 
7.6 × 105
 
 
3 - 18 hours
1
 
1.0 × 106
1.0 × 106
 
 
2
 
1.1 × 106
 
 
 
3
 
1.0 × 106
 
 
3 - 24 hours
1
 
1.2 × 106
1.2 × 106
 
 
2
 
1.2 × 106
 
  3 1.2 × 106 
CFU recovered from control samples

Protocol 2- residual sanitizer activity

A sanitization test was followed as described above (Protocol 1) using 4 replicates per material. Post this initial test a Gardner apparatus was used to simulate surface wear of the test and control samples. The abrasion tester was used at a speed of 2.25 to 2.5 for a total contact time of 4–5 seconds for one complete cycle. A wear cycle equals one pass to the left and a return pass to the right. After a minimum of 15 minutes after the wear cycle each carrier was reinoculated as described above and dried for a minimum of 30 minutes. After each set of surface wear, absolute ethanol was used to sterilize the apparatus and the foam liner and cotton cloth were changed after each wear test. Wet cycles and dry cycles were alternated and for wet wear cycles the boat assembly included a new foam liner and dry cotton cloth sprayed with sterile deionized water using a preval sprayer from a distance of 75±1 cm for not more than one second. At least 24 hours passed between the initial inoculation and final sanitizer. Overall 12 wear cycles were completed before sanitizer activity was assessed using the method outlined above. All the controls as outlined for Protocol 1 were performed.

Protocol 3- continuous bacterial reduction

A sanitization test was followed as described above (Protocol 1) using 5 replicates per each material tested. The carriers were consecutively inoculated for 8 times by adding the challenge microorganism at 0, 3, 6, 9, 12, 15, 18 and 21 hours. Efficacy was assessed at 2, 6, 12, 18 and 24 hours, which corresponds to 1, 2, 4, 6, and 8 inoculations. After exposure the carriers were transferred to a neutralizer solution and sonicated and rotated to mix. Within one hour, serial dilutions (10−1 to 10−4) were spread on plates using appropriate media and incubated for 48 hours for colony observation and enumeration. All the controls as outlined for Protocol 1 were performed.

Results

The challenge microorganisms were confirmed for purity by Gram stain and colony morphology. Controls demonstrated that the organic soil, carrier and neutralizing medium were sterile. The neutralizing solution itself did not show any bacterial inhibition. The bacterial titers (actual CFU after taking into consideration the relevant dilutions) recovered from the control samples following the different protocols, which included air drying, sonication, and recovering the bacteria from the exposed carrier, are summarized in Table 1. Tables 2, 3 and 4 show the bacterial titers recovered from the Test samples following the various protocols and the percent reduction in the bacterial titers recovered as compared to the mean bacterial titers recovered from the control samples. All experiments conducted with the copper oxide impregnated countertops demonstrated over a 3 log (>99.9%) reduction against all organisms tested, as compared to the control countertops without copper (Tables 2, 3 and 4). Out of the 192 data points obtained (average of 4 or 5 replicates each) for the test countertops, there were only two exceptions for the continuous sanitizer activity test - with a 99.8% and 99.2% reductions against Pseudomonas aeruginosa (Table 4), which exceeds the 99% reduction requirement set up by the EPA for continuous efficacy kill rates. As determined by SEM and EDS analysis, copper oxide particles are homogenously distributed within (Figure 1D and E) and throughout the surface (Figure 1B and C) of the test countertops.
Table 2

Results from Protocol 1- Sanitizer Activity

CountertopOrganismCFU/ Recovered from control samples*LotCFU recovered from test samples% reduction **
Test 1
S. aureus
7.5 × 105
1
<1;<1;5;<1;<1
>99.9
2
18;<1;11;<1;22
>99.9
3
<1;<1;<1;<1;<1
>99.9
E. aerogenes
7.9 × 106
1
1200;790;50;1200;<1
>99.9
2
760;840;1200;800;620
>99.9
3
<1;620;<1;500;<1
>99.9
MRSA
8.5 × 105
1
<1;<1;<1;<1;<1
>99.9
2
<1;<1;<1;<1;<1
>99.9
P. aeruginosa
7 × 106
1
90;580;<1;50;160
>99.9
2
440;<1;400;<1;<1
>99.9
E. coli 0157:H7
6.6 × 106
1
470;690;450;480;380
>99.9
2
560;360;320;390;360
>99.9
Test 2S. aureus
7.5 × 105
1
<1;50;<1;80;<1
>99.9
2
280;<1;70;<1;<1
>99.9
3
<1;<1;<1;<1;<1
>99.9
E. aerogenes
7.9 × 106
1
70;540;140;650;120
>99.9
2
240;750;240;460;410
>99.9
3
770;610;410;230;450
>99.9
MRSA
8.5 × 105
1
<1;<1;<1;<1;<1
>99.9
2
<1;<1;<1;<1;<1
>99.9
P. aeruginosa
7.0 × 106
1
820;740;600;880;890
>99.9
2
930;840;730;870;990
>99.9
E. coli 0157:H76.6 × 1061
640;720;300;700;700
>99.9
2660;540;490;760;300>99.9

*Values taken from Table 1.

**Compared to control, each number represents an average of 5 replicates per manufacturing lot. Either 2 or 3 lots were examined per organism.

Table 3

Results from protocol 2- residual sanitizer efficacy

CountertopOrganismCFU recovered from control samples*LotCFU recovered from test samples% reduction**
Test 1- Initial
S. aureus
1.3 × 106
1
<1.5;<1.5;<1.5;<1.5
>99.9
2
<1.5;<1.5;<1.5;<1.5
>99.9
3
<1.5;<1.5;<1.5;<1.5
>99.9
E. aerogenes
1.1 × 106
1
<1.5;<1.5;<1.5;<1.5
>99.9
2
<1.5;<1.5;<1.5;<1.5
>99.9
3
390;<1.5;<1.5;<1.5
>99.9
MRSA
7.5 × 105
1
<1.5;<1.5;<1.5;<1.5
>99.9
2
<1.5;<1.5;<1.5;<1.5
>99.9
P. aeruginosa
1.3 × 106
1
<1.5;<1.5;<1.5;<1.5
>99.9
2
<1.5;<1.5;<1.5;90
>99.9
E. coli 0157:H7
1.1 × 106
1
<1.5;<1.5;<1.5;<1.5
>99.9
2
<1.5;<1.5;<1.5;<1.5
>99.9
Test 1- Final
S. aureus
1.1 × 106
1
<1.5;<1.5;<1.5;<1.5
>99.9
2
<1.5;<1.5;<1.5;<1.5
>99.9
3
<1.5;<1.5;<1.5;<1.5
>99.9
E. aerogenes
1.2 × 106
1
<1.5;<1.5;<1.5;<1.5
>99.9
2
<1.5;<1.5;<1.5;<1.5
>99.9
3
<1.5;<1.5;<1.5;<1.5
>99.9
MRSA
6.9 × 105
1
<1.5;<1.5;<1.5;<1.5
>99.9
2
<1.5;<1.5;<1.5;<1.5
>99.9
P. aeruginosa
2.0x106
1
<1.5;<1.5;<1.5;<1.5
>99.9
2
<1.5;<1.5;<1.5;<1.5
>99.9
E. coli 0157:H7
9.4 × 105
1
<1.5;<1.5;<1.5;<1.5
>99.9
2
<1.5;<1.5;<1.5;<1.5
>99.9
Test 2- Initial
S. aureus
1.3 × 106
1
4.5;<1.5;<1.5;<1.5
>99.9
2
<1.5;<1.5;<1.5;200
>99.9
3
<1.5;<1.5;<1.5;240
>99.9
E. aerogenes
1.1 × 106
1
<1.5;60;180;<1.5
>99.9
2
9;150;420;<1.5
>99.9
3
<1.5;<1.5;<1.5;<1.5
>99.9
MRSA
7.6 × 105
1
<1.5;<1.5;<1.5;<1.5
>99.9
2
<1.5;<1.5;<1.5;<1.5
>99.9
P. aeruginosa
1.3 × 106
1
150;<1.5;9;230
>99.9
2
450;570;<1.5;<1.5
>99.9
E. coli 0157:H7
1.1 × 106
1
<1.5;60;180;<1.5
>99.9
2
90;150;420;<1.5
>99.9
Test 2- FinalS. aureus
1.1 × 106
1
<1.5;<1.5;<1.5;<1.5
>99.9
2
<1.5;330;<1.5;<1.5
>99.9
3
<1.5;<1.5;<1.5;<1.5
>99.9
E. aerogenes
1.2 × 106
1
380;<1.5;<1.5;<1.5
>99.9
2
<1.5;<1.5;<1.5;320
>99.9
3
<1.5;<1.5;<1.5;<1.5
>99.9
MRSA
6.9 × 105
1
<1.5;<1.5;<1.5;<1.5
>99.9
2
<1.5;<1.5;<1.5;<1.5
>99.9
P. aeruginosa
2.0 × 106
1
<1.5;<1.5;<1.5;<1.5
>99.9
2
<1.5;<1.5;<1.5;<1.5
>99.9
E. coli 0157:H79.4 × 1051
<1.5;<1.5;<1.5;<1.5
>99.9
2<1.5;<1.5;<1.5;<1.5>99.9

*Values taken from Table 1.

**Compared to control, each number represents an average of 4 replicates per manufacturing lot. Either 2 or 3 lots were examined per organism.

Table 4

Results from protocol 3- continuous self sanitizing activity

CountertopOrganismCFU recovered from control samplesLotCFU recovered from test samples% reduction**
Test 1–2 hours
S. aureus
9.3 × 105
1
220;340;500;670;290
>99.9
2
420;270;290;320;220
>99.9
3
380;420;340;290;270
>99.9
E. aerogenes
2.0 × 106
1
11;220;<1<1<1
>99.9
2
<1;100;220;<1;<1
>99.9
3
80;40;170;80
>99.9
MRSA
4.0 × 105
1
<1;<1;<1;<1;<1
>99.9
2
<1;<1;<1;<1;<1
>99.9
P. aeruginosa
2.5 × 105
1
480;370;480;180;120
99.9
2
420;480;240;450;360
99.8
E. coli 0157:H7
2.6 × 105
1
<1;<1;<1;<1;<1
>99.9
2
140;<1;<1;<1;150
99.9
Test 1–6 hours
S. aureus
1.8 × 106
1
<1;<1;<1;<1;<1
>99.9
2
<1;<1;<1;<1;<1
>99.9
3
<1;<1;<1;<1;<1
>99.9
E. aerogenes
3.9 × 106
1
<1;<1;<1;<1;<1
>99.9
2
<1;<1;<1;<1;<1
>99.9
3
<1;<1;<1;<1;<1
>99.9
MRSA
8.8 × 105
1
<1;<1;<1;<1;<1
>99.9
2
<1;<1;<1;<1;<1
>99.9
P. aeruginosa
5.2 × 105
1
<1;<1;<1;<1;<1
>99.9
2
<1;170;<1;<1;<1
>99.9
E. coli 0157:H7
5.3 × 105
1
<1;<1;<1;<1;<1
>99.9
2
<1;<1;<1;<1;<1
>99.9
Test 1–12 hours
S. aureus
2.5 × 106
1
<1;<1;<1;<1;<1
>99.9
2
<1;<1;<1;<1;<1
>99.9
3
<1;<1;<1;<1;<1
>99.9
E. aerogenes
4.7 × 106
1
<1;<1;<1;<1;<1
>99.9
2
<1;<1;<1;<1;<1
>99.9
3
<1;<1;<1;<1;<1
>99.9
MRSA
1.0 × 106
1
<1;<1;<1;<1;<1
>99.9
2
<1;<1;<1;<1;<1
>99.9
P. aeruginosa
7.2 × 105
1
<1;<1;<1;<1;<1
>99.9
2
<1;<1;<1;<1;<1
>99.9
E. coli 0157:H7
7.7 × 105
1
<1;<1;<1;<1;<1
>99.9
2
<1;<1;<1;<1;<1
>99.9
Test 1–18 hours
S. aureus
3.6 × 106
1
<1;<1;<1;<1;<1
>99.9
2
<1;<1;<1;<1;<1
>99.9
3
<1;<1;<1;<1;<1
>99.9
E. aerogenes
5.6 × 106
1
<1;<1;<1;<1;<1
>99.9
2
<1;<1;<1;<1;<1
>99.9
3
<1;<1;<1;<1;<1
>99.9
MRSA
1.7 × 106
1
<1;<1;<1;<1;<1
>99.9
2
<1;<1;<1;<1;<1
>99.9
P. aeruginosa
9.6 × 105
1
<1;<1;<1;<1;<1
>99.9
2
<1;<1;<1;<1;<1
>99.9
E. coli 0157:H7
1.0 × 106
1
<1;<1;<1;<1;<1
>99.9
2
<1;<1;<1;<1;<1
>99.9
Test 1–24 hours
S. aureus
4.6 × 106
1
<1;<1;<1;<1;<1
>99.9
2
<1;<1;<1;<1;<1
>99.9
3
<1;<1;<1;<1;<1
>99.9
E. aerogenes
7.9 × 106
1
<1;<1;<1;<1;<1
>99.9
2
<1;<1;<1;<1;<1
>99.9
3
<1;<1;<1;<1;<1
>99.9
MRSA
1.8 × 106
1
<1;<1;<1;<1;<1
>99.9
2
<1;<1;<1;<1;<1
>99.9
P. aeruginosa
9.7 × 105
1
<1;<1;<1;<1;<1
>99.9
2
<1;<1;<1;<1;<1
>99.9
E. coli 0157:H7
1.2 × 106
1
<1;<1;<1;<1;<1
>99.9
2
<1;<1;<1;<1;<1
>99.9
Test 2–2 hours
S. aureus
9.3 × 105
1
760;580;770;730;550
>99.9
2
780;770;520;540;460
>99.9
3
480;420;420;450;410
>99.9
E. aerogenes
2.0 × 106
1
250;240;460;250;280
>99.9
2
620;640;330;340;260
>99.9
3
360;240;280;220;270
>99.9
MRSA
4.0 × 105
1
<1;<1;<1;<1;<1
>99.9
2
<1;<1;<1;<1;<1
>99.9
P. aeruginosa
2.5 × 105
1
260;200;540;200;400
99.9
2
200;410;560;280;680
99.2
E. coli 0157:H7
2.6 × 105
1
<1;130;210;<1;30
>99.9
2
440;250;170;390;130
>99.9
Test 2–6 hours
S. aureus
1.8 × 106
1
280;260;330;230;700
>99.9
2
320;300;220;260;200
>99.9
3
160;120;100;140;180
>99.9
E. aerogenes
3.9 × 106
1
<1;<1;<1;<1;<1
>99.9
2
<1;<1;<1;<1;<1
>99.9
3
<1;<1;<1;<1;<1
>99.9
MRSA
8.8 × 105
1
<1;<1;<1;<1;<1
>99.9
2
<1;<1;<1;<1;<1
>99.9
P. aeruginosa
5.2 × 105
1
<1;<1;<1;<1;<1
>99.9
2
<1;<1;<1;<1;<1
>99.9
E. coli 0157:H7
5.3 × 105
1
<1;<1;<1;<1;<1
>99.9
2
<1;<1;<1;<1;<1
>99.9
Test 2–12 hours
S. aureus
2.5 × 106
1
<1;<1;<1;<1;<1
>99.9
2
<1;<1;<1;<1;<1
>99.9
3
<1;<1;<1;<1;<1
>99.9
E. aerogenes
4.7 × 106
1
<1;<1;<1;<1;<1
>99.9
2
<1;<1;<1;<1;<1
>99.9
3
<1;<1;<1;<1;<1
>99.9
MRSA
1.0 × 106
1
<1;<1;<1;<1;<1
>99.9
2
<1;<1;<1;<1;<1
>99.9
P. aeruginosa
7.2 × 105
1
<1;<1;<1;<1;<1
>99.9
2
<1;<1;<1;<1;<1
>99.9
E. coli 0157:H7
7.7 × 105
1
<1;<1;<1;<1;<1
>99.9
2
<1;<1;<1;<1;<1
>99.9
Test 2–18 hours
S. aureus
3.6 × 106
1
<1;<1;<1;<1;<1
>99.9
2
<1;<1;<1;<1;<1
>99.9
3
<1;<1;<1;<1;<1
>99.9
E. aerogenes
5.6 × 106
1
<1;<1;<1;<1;<1
>99.9
2
<1;<1;<1;<1;<1
>99.9
3
<1;<1;<1;<1;<1
>99.9
MRSA
1.7 × 106
1
<1;<1;<1;<1;<1
>99.9
2
<1;<1;<1;<1;<1
>99.9
P. aeruginosa
9.6 × 105
1
<1;<1;<1;<1;<1
>99.9
2
<1;<1;<1;<1;<1
>99.9
E. coli 0157:H7
1.0 × 106
1
<1;<1;<1;<1;<1
>99.9
2
<1;<1;<1;<1;<1
>99.9
Test 2–24 hoursS. aureus
4.6 × 106
1
<1;<1;<1;<1;<1
>99.9
2
<1;<1;<1;<1;<1
>99.9
3
<1;<1;<1;<1;<1
>99.9
E. aerogenes
7.9 × 106
1
<1;<1;<1;<1;<1
>99.9
2
<1;<1;<1;<1;<1
>99.9
3
<1;<1;<1;<1;<1
>99.9
MRSA
1.8 × 106
1
<1;<1;<1;<1;<1
>99.9
2
<1;<1;<1;<1;<1
>99.9
P. aeruginosa
9.7 × 105
1
<1;<1;<1;<1;<1
>99.9
2
<1;<1;<1;<1;<1
>99.9
E. coli 0157:H71.2 × 1061
<1;<1;<1;<1;<1
>99.9
2<1;<1;<1;<1;<1>99.9

*Values taken from Table 1.

**Compared to control, each number represents an average of 5 replicates per manufacturing lot. Either 2 or 3 lots were examined per organism.

Results from Protocol 1- Sanitizer Activity *Values taken from Table 1. **Compared to control, each number represents an average of 5 replicates per manufacturing lot. Either 2 or 3 lots were examined per organism. Results from protocol 2- residual sanitizer efficacy *Values taken from Table 1. **Compared to control, each number represents an average of 4 replicates per manufacturing lot. Either 2 or 3 lots were examined per organism. Results from protocol 3- continuous self sanitizing activity *Values taken from Table 1. **Compared to control, each number represents an average of 5 replicates per manufacturing lot. Either 2 or 3 lots were examined per organism.

Discussion

Bacteria can persist on inanimate surfaces for months [30] and can be a potential source for outbreaks of nosocomial infections [18,19,27]. Thus using self-sanitizing surfaces can be a very important adjunct in the fight against nosocomial pathogens [31]. The data collected under GLP independent testing using a predefined concentration of cultivated ATCC referenced bacterial strains, demonstrated the antimicrobial properties of Cupron copper oxide impregnated countertops. Protocol number 1 tested the capacity of copper oxide infused countertops to kill a number of cultivated pathogens (Table 2) under conditions prescribed by the US EPA for the in vitro testing of the antimicrobial efficacy of copper oxide particles suspended in a plastic matrix. The organisms tested constitute a broad representation of current HAI organisms, and with over a three log reduction (>99.9%) achieved within 2 hours of exposure the authors conclude that these copper oxide infused countertops can be an additional tool for bioburden reduction and potentially reducing the risk of HAI. Importantly, as demonstrated by using Protocol 2, simulating prolonged surface wear, the countertops continue to be highly efficacious even after 12 consecutive wet and dry wear and inoculation cycles (Table 3), simulating surface abrasion that occurs due to cleaning and use. Despite the erosion of the countertops’ surface, there was no reduction in biocidal efficacy. This is explained by the distribution of the copper oxide particles throughout the matrix, on and within the surface (Figure 1), and the appearance of “new” particles on the surface as the countertop surface is eroded. This property of the countertops practically endows them with biocidal properties for the life of the product. Protocol 3 demonstrated that the countertops are efficacious to consecutive bacterial inoculations (Table 4) in the same exact spot, indicating that the countertops do not lose their biocidal efficacy following bacterial kill, but maintain this biocidal property continuously. Copper has a long history as an antimicrobial and preventative measure and metallic copper countertops have previously been approved for EPA public health claims [32]. Field trials of these countertops have demonstrated the reduction in bioburden in a variety of clinical settings [33-37] and a reduction in the risk of infections [38,39]. Based on the data presented in this publication, Cupron Enhanced EOS Surfaces infused with copper have been approved for public health claims relating to their anti bacterial efficacy. Some of the approved health claims are a) “This surface continuously reduces bacterial* contamination achieving a 99.9% reduction within two hours of exposure.”; b) “This surface kills greater than 99.9% of Gram negative and Gram positive bacteria* within two hours of exposure.”; c) “This surface kills greater than 99.9% of bacteria* within two hours and continues to kill 99% of bacteria* even after repeated contamination.”; and d) “This surface helps inhibit the buildup and growth of bacteria* within two hours of exposure between routine cleaning and sanitizing steps”. *Testing demonstrates effective antibacterial activity against Staphylococcus aureus (ATCC 6538), Enterobacter aerogenes (ATCC 13048), MRSA (ATCC 33592), Escherichia coli O157:H7 (ATCC 35150) and Pseudomonas aeruginosa (ATCC 15442). These non-porous Cupron copper oxide containing solid surfaces possess comparable efficacy to the metallic hard surfaces, however represent a much more feasible alternative to the metallic surfaces as they are expected to be significantly more affordable and aesthetically more pleasing. Field trials are ongoing at the time of publication to demonstrate the efficacy of these countertops in a “real world” setting (Borkow and Monk, unpublished). The biocidal properties of copper oxide against a range of organisms have also been previously demonstrated [40-43]. Limitations of this study include that the data is based upon ATCC laboratory strains and conducted in a controlled setting such as a laboratory, however further work is ongoing utilizing field trials of the surface to demonstrate the efficacy in real world applications. Bacterial resistance to biocidal control agents is of concern in infection prevention and can be exemplified by highly antibiotic resistant bacteria (with up to 2200-fold decreased sensitivity to the antibiotic (e.g. [44]) that have evolved in less than 50 years of antibiotic usage, making infected patient treatment extremely difficult (e.g. [45]). Consequently, the possibility of development of resistance to biocides is a real concern [46,47]. Importantly, as opposed to antibiotics, despite evolving in the continued presence of copper, no microorganisms that are highly resistant to copper have been found, but only microorganisms with increased copper tolerance [31]. Importantly, no resistant bacteria evolved in vitro when repeatedly and consecutively exposed to fabrics containing copper oxide particles [42]. The reason why no resistance to copper is found in microorganisms exposed to constant relatively high doses of copper, is because copper exerts its biocidal/antimicrobial activity not through one mechanism (as most antibiotics), but through several parallel non-specific mechanisms [48,49]. Both metallic copper and copper oxide particles, in the presence of humidity, even that present in air, release copper ions. The released copper ions can migrate and reach the microorganisms even though they may not be in direct contact with the copper oxide particles. These ions can cause plasma membrane permeabilization, membrane lipid peroxidation, alteration of proteins and inhibition of their biological assembly and activity, and denaturation of nucleic acids [48,49]. It is likely that the first site that copper ions damage is the microorganisms’ envelope via electrostatic forces [50], altering the membrane integrity and permeability [51,52]. Copper ions can also cause conformational changes in the structure of intracellular or membrane proteins or in the proteins active site also by direct interaction or by displacing essential metals from their native binding sites in the proteins (e.g. [53,54]). Furthermore, the redox cycling between Cu2+ and Cu1+, which can catalyze the production of highly reactive hydroxyl radicals, can subsequently damage lipids, proteins, DNA and other biomolecules [48,55]. In addition, metallic copper, as well as cuprous oxide particles, in the absence of humidity, cause massive membrane damage and kill microorganisms within minutes via direct “contact killing” [56-58]. Apparently, the metal-bacterial contact damages the cell envelope, which, in turn, makes the cells susceptible to further damage by copper ions [58]. Microorganisms cannot cope when exposed to high concentrations of copper and are irreversibly damaged, as demonstrated also in this study. Thus, the development of resistant bacteria to copper due to the introduction of the copper containing countertops to the hospital environment is not a concern. With the ongoing HAI problem and the role of fomites and the environment being more clearly defined, the role of antimicrobial products with EPA approved public health claims, above and beyond the treated article claims and with clinical data supporting their role in HAI prevention, will become more important.

Conclusion

The tested Cupron Enhanced EOS Surfaces containing copper oxide kill above 99.9% of a wide range of bacteria within two hours of exposure and continue to do so even after repeated contamination and multiple wet and dry abrasion cycles, passing all the acceptance criteria required by the EPA. These biocidal surfaces thus may be an important adjunct to be used in hospital settings to reduce environmental bioburden and potentially nosocomial infections.

Abbreviations

CFU: Colony forming units; EDS: Energy-dispersive X-ray spectroscopy; EPA: Environmental Protection Agency; FBS: Fetal bovine serum; GLP: Good Laboratory Practice; HAI: Hospital Acquired Infections; MRSA: Methicillin resistant Staphylococcus aureus; PBS: Phosphate buffered solution; SEM: Scanning Electron Microscopy; TSA: Tryptic Soy Agar.

Competing interests

KT is an employee of EOS Surfaces. ABM, VK and GB are employees of Cupron Inc. This study was funded by Cupron Inc. and EOS Surfaces that developed the antimicrobial surfaces.

Authors’ contributions

ABM and GB made substantial contributions to conception, design, analysis and interpretation of data of the study, and writing the manuscript; VK and KT were key in designing and developing the test materials studied, and revising the manuscript critically for important intellectual content. All authors read and approved the final manuscript.
  51 in total

Review 1.  Methicillin-resistant Staphylococcus aureus: an update.

Authors:  Rajaraman Durai; Philip C H Ng; Happy Hoque
Journal:  AORN J       Date:  2010-05       Impact factor: 0.676

2.  Costs attributable to healthcare-acquired infection in hospitalized adults and a comparison of economic methods.

Authors:  Rebecca R Roberts; R Douglas Scott; Bala Hota; Linda M Kampe; Fauzia Abbasi; Shari Schabowski; Ibrar Ahmad; Ginevra G Ciavarella; Ralph Cordell; Steven L Solomon; Reidar Hagtvedt; Robert A Weinstein
Journal:  Med Care       Date:  2010-11       Impact factor: 2.983

3.  Neutralizing viruses in suspensions by copper oxide-based filters.

Authors:  Gadi Borkow; Robert W Sidwell; Donald F Smee; Dale L Barnard; John D Morrey; Humberto H Lara-Villegas; Yonat Shemer-Avni; Jeffrey Gabbay
Journal:  Antimicrob Agents Chemother       Date:  2007-04-30       Impact factor: 5.191

4.  Microbial contamination of hospital bed handsets.

Authors:  John M Young; Mubariz Naqvi; Lance Richards
Journal:  Am J Infect Control       Date:  2005-04       Impact factor: 2.918

5.  Copper inhibits the protease from human immunodeficiency virus 1 by both cysteine-dependent and cysteine-independent mechanisms.

Authors:  A R Karlström; R L Levine
Journal:  Proc Natl Acad Sci U S A       Date:  1991-07-01       Impact factor: 11.205

Review 6.  Metals, toxicity and oxidative stress.

Authors:  M Valko; H Morris; M T D Cronin
Journal:  Curr Med Chem       Date:  2005       Impact factor: 4.530

Review 7.  Antimicrobial susceptibility of pathogens isolated from more than 10,000 patients with infectious respiratory diseases: a 25-year longitudinal study.

Authors:  Hajime Goto; Kaoru Shimada; Hideo Ikemoto; Toyoko Oguri
Journal:  J Infect Chemother       Date:  2009-12       Impact factor: 2.211

8.  Role of copper in reducing hospital environment contamination.

Authors:  A L Casey; D Adams; T J Karpanen; P A Lambert; B D Cookson; P Nightingale; L Miruszenko; R Shillam; P Christian; T S J Elliott
Journal:  J Hosp Infect       Date:  2009-11-20       Impact factor: 3.926

9.  Role of copper oxides in contact killing of bacteria.

Authors:  Michael Hans; Andreas Erbe; Salima Mathews; Ying Chen; Marc Solioz; Frank Mücklich
Journal:  Langmuir       Date:  2013-12-17       Impact factor: 3.882

10.  Contamination, disinfection, and cross-colonization: are hospital surfaces reservoirs for nosocomial infection?

Authors:  Bala Hota
Journal:  Clin Infect Dis       Date:  2004-09-27       Impact factor: 9.079

View more
  10 in total

1.  Antimicrobial Activity of Copper Alloys Against Invasive Multidrug-Resistant Nosocomial Pathogens.

Authors:  Ozgen Koseoglu Eser; Alper Ergin; Gulsen Hascelik
Journal:  Curr Microbiol       Date:  2015-06-05       Impact factor: 2.188

Review 2.  Engineering and Application Perspectives on Designing an Antimicrobial Surface.

Authors:  Boyi Song; Ershuai Zhang; Xiangfei Han; Hui Zhu; Yuanjie Shi; Zhiqiang Cao
Journal:  ACS Appl Mater Interfaces       Date:  2020-02-03       Impact factor: 9.229

Review 3.  The Use of Copper as an Antimicrobial Agent in Health Care, Including Obstetrics and Gynecology.

Authors:  Linda P Arendsen; Ranee Thakar; Abdul H Sultan
Journal:  Clin Microbiol Rev       Date:  2019-08-14       Impact factor: 26.132

4.  Reduction of Health Care-Associated Infections (HAIs) with Antimicrobial Inorganic Nanoparticles Incorporated in Medical Textiles: An Economic Assessment.

Authors:  Finbarr Murphy; Anat Tchetchik; Irini Furxhi
Journal:  Nanomaterials (Basel)       Date:  2020-05-23       Impact factor: 5.076

5.  In Situ Monitoring of the Antibacterial Activity of a Copper-Silver Alloy Using Confocal Laser Scanning Microscopy and pH Microsensors.

Authors:  Nicole Ciacotich; Kasper Nørskov Kragh; Mads Lichtenberg; Jens Edward Tesdorpf; Thomas Bjarnsholt; Lone Gram
Journal:  Glob Chall       Date:  2019-07-15

Review 6.  Copper Surfaces in Biofilm Control.

Authors:  Inês B Gomes; Manuel Simões; Lúcia C Simões
Journal:  Nanomaterials (Basel)       Date:  2020-12-11       Impact factor: 5.076

7.  Antiviral activity of galvanic microcells of zinc and copper contained within painted surfaces.

Authors:  Wojciech Spisak; Mariusz Kaszczyszyn; Mateusz Szar; Jarosław Kozak; Krzysztof Stachowicz
Journal:  Sci Rep       Date:  2022-01-25       Impact factor: 4.379

8.  Effectiveness of Copper-Impregnated Solid Surfaces on Lowering Microbial Bio-Burden Levels in an Acute Care Hospital.

Authors:  Piyali Chatterjee; Marjory D Williams; John D Coppin; Yonhui Allton; Hosoon Choi; Julie Ann D Martel; John E Zeber; Richard E Nelson; Curtis J Donskey; Chetan Jinadatha
Journal:  Open Forum Infect Dis       Date:  2020-06-19       Impact factor: 3.835

9.  Using Copper to Improve the Well-Being of the Skin.

Authors:  Gadi Borkow
Journal:  Curr Chem Biol       Date:  2014-08

10.  Surface area wiped, product type, and target strain impact bactericidal efficacy of ready-to-use disinfectant Towelettes.

Authors:  Alyssa M West; Carine A Nkemngong; Maxwell G Voorn; Tongyu Wu; Xiaobao Li; Peter J Teska; Haley F Oliver
Journal:  Antimicrob Resist Infect Control       Date:  2018-10-11       Impact factor: 4.887

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.